A 2004 randomized controlled trial tested this directly in women with androgenetic alopecia and diffuse hair loss
What Are Growth Hormone Stimulating Peptides, Semorelin, and Ipamorelin-CJC1295
Expected Timeline Weeks 14: Appetite change Weeks 48: Visible weight change Weeks 812: Metabolism becomes more efficient 12+ weeks: Steady monthly results Who Should Avoid GLP-1 (Rare Cases) History of Medullary Thyroid Cancer Family history of MEN2 Uncontrolled hypothyroidism (TSH extremely high) Severe GI disorders (gastroparesis, bowel obstruction) I will not start GLP-1 if your bloodwork is unstable or you show severe symptoms like: Persistent fast heart rate Severe constipation Unmanaged fatigue Gastrointestinal blockage history What to Expect If You Start GLP-1 With Hypothyroidism Heres the exact guidance I give patients: Dose Titration Start low
This ERMCS length reduction was accompanied by a reduced number of ERMCSs per mitochondrial area in exendin-4-stimulated versus vehicle-exposed WT INS-1 832/3 cells, assessed using a splitFAST approach as in ref
CJC-1295, a GHRH analogue, has been reported to produce sustained increases in growth hormone and IGF-I in healthy adults, while Ipamorelin was characterized as the first selective growth hormone secretagogue, stimulating GH release without significantly affecting ACTH or cortisol
